Brugada P, Smeets J L, Brugada J, Farré J
Department of Cardiology, University of Limburg, The Netherlands.
Cardiovasc Drugs Ther. 1990 Jun;4 Suppl 3:619-23. doi: 10.1007/BF00357040.
Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II beta-blocking agents with the Class III properties that prolong repolarization. The Class II action exerts a marked effect on atrioventricular nodal conduction and makes sotalol a suitable drug for the treatment of adrenergic-induced supraventricular tachycardias. Sotalol helps to prevent or slow supraventricular arrhythmias involving the atrioventricular node as part of a reentrant pathway and also helps to control the ventricular rate during supraventricular arrhythmias conducted to the ventricles over the normal atrioventricular pathway. The capacity of conduction of accessory pathways is diminished by sotalol, thereby decreasing the ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. The effects of sotalol on conduction of the cardiac impulse (Class I effects) have been probably overlooked and those on true refractoriness (Class III effects) overestimated.
索他洛尔具有几乎独一无二的抗心律失常特性,它将Ⅱ类β受体阻滞剂的特性与延长复极的Ⅲ类特性结合在一起。Ⅱ类作用对房室结传导有显著影响,使索他洛尔成为治疗肾上腺素能诱发的室上性心动过速的合适药物。索他洛尔有助于预防或减缓涉及房室结作为折返途径一部分的室上性心律失常,也有助于控制通过正常房室途径传导至心室的室上性心律失常期间的心室率。索他洛尔可降低旁路传导能力,从而降低预激综合征患者房颤时的心室率。索他洛尔对心脏冲动传导的影响(Ⅰ类作用)可能被忽视了,而对真正不应期的影响(Ⅲ类作用)则被高估了。